Bio-Rad Laboratoriesvs.Quest Diagnostics
BIO vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Quest Diagnostics is about 2.6× larger than Bio-Rad Laboratories by market cap; Quest Diagnostics trades at the lower P/E (23.6 vs 43.0); year to date, Quest Diagnostics leads (+30.8% vs +21.4%).
Side by side
| BIO | DGX | |
|---|---|---|
| Market cap | $9.6B | $25.1B |
| Price | $360.40 | $230.81 |
| Today | −2.0% | +1.7% |
| Return YTD | +21.4% | +30.8% |
| Return 1Y | +24.1% | +24.8% |
| Since June 26, 2026 | +19.8% | +10.0% |
| P/E | 43.0 | 23.6 |
| P/S | 3.7 | 2.2 |
| P/B | 1.3 | 3.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →More BIO & DGX comparisons
Other head-to-heads in the Diagnostics segment.